In a significant move poised to reshape the landscape of thoracic care, medical imaging innovators Optellum and Coreline Soft have announced a strategic partnership aimed at integrating their respective artificial intelligence (AI) technologies. The collaboration seeks to create a comprehensive, end-to-end ecosystem for lung nodule detection, risk stratification, and patient management, addressing one of the most critical challenges in modern oncology: the early diagnosis of lung cancer.
By integrating Coreline Soft’s FDA-cleared AVIEW Lung Nodule CADe (Computer-Aided Detection) software into Optellum’s sophisticated LungOS platform, the two companies are positioning themselves to provide clinicians with a unified, data-driven approach to thoracic health. This synergy combines precise image-based detection with advanced risk assessment and clinical workflow management, aiming to reduce the diagnostic gap that often leads to late-stage lung cancer presentation.
The Core of the Integration: Technical Synergy
The fundamental challenge in lung cancer screening is the high volume of "incidental" nodules—small growths found on chest CT scans conducted for unrelated reasons. Determining which of these nodules require urgent intervention and which can be monitored safely is a process fraught with human variability and administrative complexity.
The partnership leverages the strengths of both organizations:
- Coreline Soft’s AVIEW Lung Nodule CADe: Renowned for its clinical rigor, this AI-driven tool excels at the initial detection of lung nodules. Its ability to process high-resolution imagery allows for the identification of subtle markers that might otherwise be overlooked in a busy clinical setting.
- Optellum’s LungOS Platform: Acting as the "operating system" for lung care, LungOS is not merely a detection tool but a management powerhouse. It features the Virtual Nodule Clinic, which utilizes proprietary AI for patient discovery and lung cancer prediction.
By embedding AVIEW within LungOS, the collaboration provides a seamless transition from raw image analysis to actionable clinical insight. This removes the "siloed" nature of diagnostic software, allowing radiologists and pulmonologists to view detection data alongside automated risk assessments in a single interface.
Chronology of a Strategic Shift
The road to this partnership is marked by a series of steady advancements in the field of AI-assisted radiology.
- Early Innovation Phase: Over the past decade, both companies independently sought to solve the "lung cancer paradox"—the fact that while lung cancer is highly treatable in its early stages, most cases are caught too late. Coreline Soft focused on the technical precision of detection, earning FDA clearance and establishing a strong presence in the Asian and North American markets.
- The Rise of LungOS: Simultaneously, Optellum carved a niche in the Western markets with its Virtual Nodule Clinic. By focusing on "reimbursed" nodule risk assessment, they provided a business case for hospitals to adopt AI, transforming AI from a "nice-to-have" novelty into a fundamental clinical utility.
- The Convergence: Recognition of the complementary nature of their products led to exploratory talks in early 2026. Both firms identified that while detection (CADe) is essential, it is incomplete without decision support (CADx) and follow-up management.
- The Announcement (August 2026): The formalization of this partnership marks the transition from standalone software solutions to a "platform-first" approach in pulmonary medicine. The move signifies a broader industry trend where specialized AI vendors are moving toward interoperability to offer comprehensive care pathways.
Supporting Data: The Clinical Necessity
The rationale behind this integration is backed by mounting evidence that AI intervention significantly improves patient outcomes. According to data from international screening trials, the use of AI in chest CT analysis can improve the sensitivity of nodule detection by a substantial margin, reducing false negatives that lead to delayed diagnoses.
Furthermore, the "incidental nodule" problem is reaching crisis proportions in healthcare systems globally. With the aging population and the increased use of chest CT scans for non-lung-related issues (such as cardiac assessments or trauma), radiologists are facing an unprecedented workload.
- Efficiency Gains: Studies suggest that AI-powered triage can reduce the time taken for a radiologist to report on a chest CT by up to 25%, allowing for more rapid triaging of patients who require urgent follow-up.
- Consistency: AI provides a standardized metric for nodule volume and growth rate, removing the inter-observer variability that often leads to inconsistent clinical advice.
- Global Reach: The integration is designed to be scalable across international markets. While regulatory requirements vary, the underlying architecture of LungOS is already cleared for use in the US, Australia, the UK, the EU, and Switzerland—territories that represent the bulk of the global demand for advanced lung cancer diagnostics.
Official Responses: A Shared Vision
The leadership of both organizations has expressed strong optimism regarding the partnership, emphasizing that the move is driven by a desire to improve patient outcomes rather than mere market expansion.
Dr. Johnathan Watkins, CEO of Optellum, noted: "Optellum is building LungOS into a unified operating system for lung cancer and thoracic care more broadly. Our intended collaboration with Coreline Soft reflects a shared commitment to giving clinicians and health systems the tools they need to support earlier, more confident lung nodule assessment."
He further highlighted the complementary nature of the firms, stating, "Coreline Soft’s commitment to clinical rigor and combined excellence has underpinned its strong track record in AI-enabled nodule detection. This is highly complementary to Optellum’s leadership in reimbursed nodule risk assessment and management. Together, we aim to support a future where no lung nodule patient is left behind."
Jin Kook Kim, CEO of Coreline Soft, echoed these sentiments, focusing on the practical benefits for medical practitioners: "Coreline Soft has been committed to advancing AI technologies that support radiologists, pulmonologists, and multidisciplinary care teams in lung cancer care. We are pleased to explore this potential collaboration with Optellum. Optellum’s LungOS platform and Virtual Nodule Clinic help healthcare institutions manage the care pathway for patients with lung nodules in a more structured way."
Implications: The Future of Thoracic Care
The implications of this partnership are far-reaching for healthcare providers, patients, and the broader MedTech industry.
For Clinicians and Hospitals
The primary beneficiaries are multidisciplinary teams—the radiologists, pulmonologists, and thoracic surgeons who work together to treat lung cancer. By centralizing data, the Optellum-Coreline integration reduces the administrative burden of tracking patient progress. It allows for the automation of "Virtual Nodule Clinics," where high-risk patients are automatically flagged and prioritized, ensuring that follow-up appointments are scheduled promptly.
For the MedTech Industry
This partnership represents a maturation of the AI in healthcare sector. The industry is moving away from a "Wild West" of fragmented, standalone applications toward a "Platform Ecosystem." Hospital IT departments are increasingly reluctant to purchase dozens of separate AI tools; they prefer integrated platforms that provide a single workflow. By joining forces, Optellum and Coreline Soft are setting a benchmark for interoperability that other AI developers will likely be forced to follow.
For Patient Outcomes
Ultimately, the goal is to shift the needle on lung cancer mortality. Lung cancer remains the leading cause of cancer-related death worldwide, largely because it is often asymptomatic until it has reached an advanced stage. The ability to automatically identify, quantify, and track incidental nodules means that more cancers will be caught at Stage I, where curative surgery is a viable option, compared to Stage IV, where options are limited and prognosis is poor.
Conclusion: A New Era of Predictive Medicine
The collaboration between Optellum and Coreline Soft is a testament to the transformative power of AI when applied with clinical precision. By integrating detection (CADe) with management (CADx), the two companies are effectively building a safety net for patients. As the technology continues to evolve, the integration will likely expand to cover other thoracic diseases, further solidifying the role of the LungOS platform as the central nervous system of modern respiratory care.
As the medical community awaits the full implementation of this integrated workflow, one thing is clear: the era of reactive diagnosis is drawing to a close. In its place, a proactive, AI-driven framework is emerging—one where technology does not replace the clinician, but rather empowers them to act with unprecedented speed, confidence, and accuracy. This partnership is not just a commercial agreement; it is a vital step toward a future where lung cancer is no longer a death sentence, but a manageable condition caught in time.
About the Author
